Chen C C, Wu M L
Department of Pharmacology, College of Medicine, National Taiwan University, Taipei.
Mol Pharmacol. 1995 Dec;48(6):995-1003.
Protein kinase C (PKC), the major receptor for tumor-promoting phorbol esters, is a family consisting of at least 12 distinct isoforms. In C6 glioma cells, short term (10 min) treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA) results in a dose-dependent translocation of PKC alpha, PKC delta and PKC theta. Long term (24 hr) treatment with appropriate doses of TPA results in the complete down-regulation of PKC delta but not of PKC alpha PKC theta. This property was used to determine which isoform might be involved in the activation of the glial cell Na(+)-H+ exchanger. It was found that (a) TPA has dose-dependent effects on PKC alpha, PKC delta, and PKC theta translocation and on Na(+)-dependent, EIPA-sensitive Na(+)-H+ exchanger stimulation; (b) the antiporter is blocked both by staurosporine and in cells in which PKC alpha, PKC delta, and PKC theta have been completely down-regulated; (c) the inactive form (alpha-TPA) of TPA, which does not include translocation of the three isoforms (alpha, delta, and theta) has no effect on the antiporter; (d) Western blot analysis demonstrated dose-dependent TPA (10, 30, 100, and 1000 nM)-induced translocation of PKC alpha, PKC delta, and PKC theta. TPA (10, 30, 100, and 1000 nM)-induced Na(+)-H+ exchanger activation was also found to be dose dependent. There was no difference in TPA-induced Na(+)-H+ exchanger activation between 30 and 100 nM; it correlated with the extent of TPA-induced PKC delta translocation over the same concentration range, suggesting that isoform responsible for the exchanger activation is PKC delta; (e) When 1 microM TPA is added after prior treatment of the cells with 10 nM TPA, an additive effect on Na(+)-H+ exchanger is seen that is not observed when the initial stimulus in 30 nM TPA, as would be expected if the PKC delta isoform were responsible for exchanger activation; (f) Finally, when PKC delta, but not PKC alpha and PKC theta, is completely down-regulated by 24-hr pretreatment with 10, 30, or 100 nM TPA, the Na(+)-H+ exchanger can no longer be stimulated by 1 microM TPA; when 1 nM TPA pretreatment is used, no down-regulation occurs and the exchanger still responds to 1 microM TPA. We have shown that the Na(+)-H+ exchanger in C6 glioma cells can be stimulated by TPA-induced PKC activation and, for the first time, that PKC delta is involved in the activation of this antiporter. Our results also suggest that different members of the PKC family within a single cell elicit specific physiological responses.
蛋白激酶C(PKC)是促肿瘤佛波酯的主要受体,是一个由至少12种不同亚型组成的家族。在C6胶质瘤细胞中,用12 - O - 十四酰佛波醇 - 13 - 乙酸酯(TPA)进行短期(10分钟)处理会导致PKCα、PKCδ和PKCθ呈剂量依赖性易位。用适当剂量的TPA进行长期(24小时)处理会导致PKCδ完全下调,但PKCα和PKCθ不会。利用这一特性来确定哪种亚型可能参与胶质细胞钠氢交换体的激活。结果发现:(a)TPA对PKCα、PKCδ和PKCθ的易位以及对钠依赖性、EIPA敏感的钠氢交换体刺激具有剂量依赖性作用;(b)钠氢交换体被星形孢菌素阻断,并且在PKCα、PKCδ和PKCθ已完全下调的细胞中也被阻断;(c)TPA的无活性形式(α - TPA),它不会导致这三种亚型(α、δ和θ)易位,对钠氢交换体没有影响;(d)蛋白质印迹分析表明TPA(10、30、100和1000 nM)诱导PKCα、PKCδ和PKCθ易位具有剂量依赖性。TPA(10、30、100和1000 nM)诱导的钠氢交换体激活也具有剂量依赖性。在30和100 nM之间,TPA诱导的钠氢交换体激活没有差异;它与相同浓度范围内TPA诱导的PKCδ易位程度相关,表明负责交换体激活 的亚型是PKCδ;(e)当细胞先用10 nM TPA预处理后再加入1 μM TPA时,会观察到对钠氢交换体的相加效应,而当初始刺激为30 nM TPA时则未观察到这种效应,这正如预期的那样,如果PKCδ亚型负责交换体激活;(f)最后,当用10、30或100 nM TPA进行24小时预处理使PKCδ完全下调,但PKCα和PKCθ未下调时,1 μM TPA不再能刺激钠氢交换体;当使用1 nM TPA预处理时,不会发生下调,交换体仍对1 μM TPA有反应。我们已经表明,C6胶质瘤细胞中的钠氢交换体可以被TPA诱导的PKC激活所刺激,并且首次表明PKCδ参与了这种反向转运体的激活。我们的结果还表明,单个细胞内PKC家族的不同成员引发特定的生理反应。